Acceleron Pharma Inc.

Genetics Institute, Inc.

Wyeth

Ludwig Institute for Cancer Research Limited

Adimab, LLC

John L Knopf

Jasbir S Seehra

Ravindra Kumar

Asya Grinberg

Robert Scott Pearsall

Dianne S Sako

Roselyne Castonguay

Yossi Dagon

James Clark

Jonathan Belk

Nathan J Sharkey

Gang Li

Matthew L Sherman

Chuanzheng Song

Ronald Kriz

Naga Venkata Sai Rajasekhar Suragani

Lioudmila Tchistiakova

Samuel Goldman

Debra D Donaldson

Davinder Gill

Xiang-Yang Tan

Angela Widom

Marion T Kasaian

Kristian Pietras

Macy X Jin

Bruce Jacobson

Jean E Bemis

Yibin Xiang

Frank Eldridge Lovering

Lihren Chen

John C McKew

Rajasekhar Naga Venkata Sai Suragani

Erik M Vogan

Jabir Seehra

Ken Attie

Seehra Jasbir

This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments, the ALK7-binding proteins inhibit or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.

ALK7 binding proteins and uses thereof

In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF3/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.

Compositions and methods for treating pulmonary hypertension

In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and antibodies that inhibit receptor-ligand interaction.

ALK1 receptor and ligand antagonists and uses thereof

In certain aspects, the disclosure provides ALK7 antagonists. In certain aspects, these ALK7 antagonists are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7 antagonists can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof. In certain aspects, these ALK7 antagonists can be used to treat or prevent cancer.

ALK7 antagonists and uses thereof

In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK7 receptor and an extracellular domain of ActRIIB In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof.

ALK7:ActRIIB heteromultimers and uses thereof

In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.

Methods and compositions for increasing red blood cells

This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.

In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.

In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.

Method for promoting bone growth using activin-actriia antagonists

ALK7:actriib heteromultimers and uses thereof

Growing community of inventors

Acton, MA, United States of America

John L Knopf